Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They
have a poor prognosis with high rates of recurrence and metastasis. The five-year survival …

DNA-targeted drugs constitute a specialized category of pharmaceuticals developed for
cancer treatment, directly influencing various cellular processes involving DNA. These drugs …

Simple Summary Leiomyosarcoma is a subtype of soft tissue sarcoma with poor outcomes
and response to currently available treatments. The goal of this review is to assess the …

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the treatment of
ovarian cancer, particularly benefiting patients whose tumors harbor genomic events that …

Targeting the DNA damage response (DDR) pathway is an emerging therapeutic approach
for leiomyosarcoma (LMS), and loss of RNase H2, a DDR pathway member, is a potentially …

Background: Mesenchymal uterine tumors are a diverse group of neoplasms with varying
biological potential. Many of these neoplasms can have overlap** morphologic …

Background Uterine leiomyosarcoma (uLMS) represents one of the most common sarcoma
histotypes, demonstrating an overall dismal prognosis. Previous studies reported uLMS to …

Introduction Soft tissue sarcomas (STS) represent a heterogenous group of rare tumors,
primarily treated with surgery. Preoperative radiotherapy is often recommended for extremity …

Genomic profiling has improved our understanding of the pathogenesis of different cancers
and led to the development of several targeted therapies, especially in epithelial tumors. In …

Despite recent advances in cancer treatment, the prognosis for uterine malignancies
(carcinoma and sarcoma) requires further improvement. Antibody–drug conjugates (ADCs) …